Review
Copyright ©The Author(s) 2022.
World J Gastroenterol. May 21, 2022; 28(19): 2034-2056
Published online May 21, 2022. doi: 10.3748/wjg.v28.i19.2034
Table 1 Demographic characteristic of cases with suspected coronavirus disease 2019-attributed acute pancreatitis
Patient characteristics
Value
Age, median (range, yr)42.0 (6-87)
Gender, male/female/NA37/44/1
Comorbidities
Hypertension22
Diabetes15
Dyslipidemia4
Heart disease3
Cerebrovascular0
Respiratory disease4
Renal dysfunction5
Obesity16
Pregnancy2
Malignancy2
History of abdominal surgery13
Others10
Alcohol consumption, none/low/heavy/NA53/9/0/20
History of smoking, never/experience/current/NA32/2/0/48
Severity of COVID-19
Non-severe/severe/critical/NA35/23/20/4
Symptoms
Fever49
Breath shortness16
Cough28
Dyspnea18
Sore throat18
Fatigue9
Headache7
Myalgia10
Anorexia13
Diarrhea16
Abdominal pain75
Nausea 39
Vomiting48
Others23
Blood test
WBC, median (range, × 103/mm3)13.10 (3.40-230.00)
PLT, median (range, × 103/mm3)235.5 (52.0-502.0)
D-Dimer, median (range, μg/mL)4.9 (0.3-17.7)
Amylase, median (range, U/L)635 (47-4530)
Lipase, median (range, U/L)895.5 (35.6-11920.0)
LDH, median (range, U/L)366.0 (170-3553)
CRP, median (range, mg/dL)8.5 (0.3-59.7)
Imaging findings (n = 75)
Pancreatic enlargement42
Peripancreatic fluid collection33
Peripancreatic inflammatory change48
Pancreatic ischemic change12
No change of pancreas6
Not visualized2
Severity of acute pancreatitis
Mild/moderate/severe/NA28/20/28/6
Therapy for COVID-19
Lopinavir/ritonavir4
Favipiravir4
Umifenovir2
Remdesivir8
Hydroxychloroquine2
Tocilizumab2
Corticosteroid (n = 53)21
Oxygen therapy (n = 69)42
Mechanical ventilation19
Therapy for acute pancreatitis
Conservative therapy/surgical drainage/NA72/4/6
Period of hospitalization, median (range, day)7.5 (2-76)
Prognosis
Alive/death/NA69/10/3